Diabetologie und Stoffwechsel 2023; 18(S 01): S64-S65
DOI: 10.1055/s-0043-1767995
Abstracts | DK 2023
Poster
Postersitzung 15

Tirzepatide Induces Weight Loss in participants with Type 2 Diabetes Regardless of Baseline BMI: A Post Hoc Analysis of SURPASS-1 through -5 Studies

Authors

  • Anita YM Kwan

    1   Eli Lilly and Company, Lilly Diabetes, Indianapolis, Indiana, United States

  • Juan M. Maldonado

    1   Eli Lilly and Company, Lilly Diabetes, Indianapolis, Indiana, United States

  • Hui Wang

    1   Eli Lilly and Company, Lilly Diabetes, Indianapolis, Indiana, United States

  • Neda Rasouli

    2   University of Colorado School of Medicine, Department of Medicine, Aurora, Colorado, United States

  • John P.H. Wilding

    3   University Hospital Aintree, Department of Cardiovascular and Metabolic Medicine, Clinical Sciences Centre, Liverpool, United Kingdom

  • Jens Aberle

    4   Universitätsklinikum Hamburg-Eppendorf, Zentrum für Innere Medizin III. Medizinische Klinik und Poliklinik (Nephrologie/Rheumatologie/Endokrinologie), Hamburg-Eppendorf, Germany
Further Information
Also available at
 
 

    Question Do the weight-lowering effects of tirzepatide (TZP) depend on baseline body mass index (BMI) in patients with type 2 diabetes (T2D)?

    Methodology TZP (5, 10, 15mg) as monotherapy or in combination with oral glucose-lowering medications medications or insulin glargine were compared to placebo, semaglutide 1mg, insulin degludec, and insulin glargine with primary endpoint at 40 weeks or 52 weeks. Body weight change in the BMI subgroups (Subgroup 1 [< 27 or ≥ 27kg/m2] and Subgroup 2 [< 30; ≥ 30 to<35; ≥ 35kg/m2]) at primary endpoint was assessed in patients while on treatment without rescue medication (efficacy estimand) in the modified intention-to-treat population, defined as all randomized patients who received at least one dose of study drug.

    Results All TZP doses (5, 10, 15mg) lowered body weight in patients with T2D irrespective of baseline BMI in both subgroups (p<0.001). The weight reductions were generally dose-dependent and absolute weight change was generally greater in higher BMI categories. The most frequent adverse events were gastrointestinal-related events that were generally mild to moderate in severity and occurred mostly during the dose-escalation period.

    Conclusion TZP-treated patients with T2D experienced weight loss across a spectrum of mean baseline BMI values in SURPASS-1 through -5 studies.


     

    Interessenkonflikt

    This study was previously presented at ADA 2022; This study was funded by Eli Lilly and Company;Authors' COI Information:Anita YM Kwan and Juan M. Maldonado are employees and shareholders of Eli Lilly and Company.; Hui Wang is an Eli Lilly contractor (TechData Service Company, King of Prussia, PA, USA) and not a shareholder of Eli Lilly.; Neda Rasouli receives research funding from Eli Lilly and Novo Nordisk, and a consultant for Eli Lilly, Novo Nordisk and Sanofi.; John P.H. Wilding is a consultant for AstraZeneca, Boehringer Ingelheim, Lilly, Napp, Novo Nordisk, Mundipharma, Rhythm Pharmaceuticals, Sanofi, and Saniona, a grant holder (University of Liverpool) for research grants for clinical trials from AstraZeneca and Novo Nordisk and has received personal honoraria / lecture fees from AstraZeneca, Boehringer Ingelheim and Napp.

    Publication History

    Article published online:
    02 May 2023

    © 2023. Thieme. All rights reserved.

    Georg Thieme Verlag
    Rüdigerstraße 14, 70469 Stuttgart, Germany